Pensionfund Sabic Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Pensionfund Sabic increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 36.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,800 shares of the medical equipment provider’s stock after purchasing an additional 5,000 shares during the period. Pensionfund Sabic’s holdings in Hologic were worth $1,355,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Caprock Group LLC bought a new stake in Hologic in the 2nd quarter worth $432,000. Quest Partners LLC grew its stake in shares of Hologic by 56.1% in the second quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider’s stock worth $3,081,000 after purchasing an additional 14,914 shares during the last quarter. Prudential PLC increased its holdings in Hologic by 79.9% during the 2nd quarter. Prudential PLC now owns 62,677 shares of the medical equipment provider’s stock valued at $4,654,000 after purchasing an additional 27,839 shares during the period. Wedbush Securities Inc. lifted its holdings in Hologic by 48.6% in the 2nd quarter. Wedbush Securities Inc. now owns 4,760 shares of the medical equipment provider’s stock worth $353,000 after buying an additional 1,556 shares during the period. Finally, Choreo LLC bought a new stake in shares of Hologic in the 2nd quarter worth approximately $393,000. 94.73% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of Hologic in a report on Thursday, December 19th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Royal Bank of Canada increased their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Evercore ISI increased their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $89.50.

Hologic Stock Up 0.8 %

HOLX opened at $73.77 on Tuesday. The stock has a market cap of $16.74 billion, a price-to-earnings ratio of 22.15, a price-to-earnings-growth ratio of 2.32 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The firm’s fifty day moving average is $76.59 and its 200 day moving average is $78.55. Hologic, Inc. has a fifty-two week low of $70.36 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.89 earnings per share. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.